Tuberculosis, Pulmonary Clinical Trial
Official title:
Different Reintroduction Regimens of Antituberculosis Drugs After Development of Hepatitis During Anti-tuberculosis Treatment
Despite the availability of effective anti-tuberculosis agents that exist to treat this
illness, hepatotoxicity during first-line drugs anti-tuberculosis medications (ATT) such as
isoniazid (INH), rifampin (RIF), and pyrazinamide (PZA) is not uncommon and limit their use.
There is no consensus on method of the reintroduction of anti-TB medications. The risk of
reintroducing of a anti-TB medications could be hazardous. There are several differences
between the guidelines from the ATS, BTS and the Task Force of the European Respiratory
Society, the WHO and the International Union Against Tuberculosis and Lung Disease about the
methods of reintroducing of anti-TB medications.
The investigators plan to do a prospective study to evaluate the outcome and safety of
reintroduction of anti-TB medications after resolution of hepatitis during anti-TB treatment
among TB patients in the investigators hospital.
Tuberculosis (TB) remains a leading health problem in both developing and developed
countries. Despite the availability of effective chemotherapeutic agents that exist to treat
this illness, hepatotoxicity during first-line drugs anti-tuberculosis medications (ATT)
such as isoniazid (INH), rifampin (RIF), and pyrazinamide (PZA) is not uncommon and limit
their use. In the case of confirmed moderate or severe drug-induced hepatotoxicity,
treatment should be interrupted and reintroduced after the hepatotoxicity has resolved.
There is no consensus on method of the reintroduction of anti-TB medications. The risk of
reintroducing of a anti-TB medications could be hazardous. There are several differences
between the guidelines from the ATS, BTS and the Task Force of the European Respiratory
Society, the WHO and the International Union Against Tuberculosis and Lung Disease about the
methods of reintroducing of anti-TB medications.
We plan to do a prospective study to evaluate the outcome and safety of reintroduction of
anti-TB medications after resolution of hepatitis during anti-TB treatment among TB patients
in our hospital.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06084715 -
The INSTITUT Study
|
||
Terminated |
NCT03028129 -
Prevention of Tuberculosis in Prisons
|
Phase 4 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Withdrawn |
NCT03862248 -
Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More
|
Phase 3 | |
Completed |
NCT03271567 -
Nanodisk-MS Assay for the Diagnosis of Active Pulmonary and Extrapulmonary Tuberculosis in Hospitalized Patients
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Active, not recruiting |
NCT04919239 -
Clinical Trial to Investigate Therapeutic Vaccine (RUTI) Against Tuberculosis (TB)
|
Phase 2 | |
Active, not recruiting |
NCT03251196 -
TB Sequel: Pathogenesis and Risk Factors of Long-term Sequelae of Pulmonary TB
|
||
Recruiting |
NCT05926466 -
BTZ-043 Dose Evaluation in Combination and Selection
|
Phase 2 | |
Recruiting |
NCT04752592 -
Evaluation of a Rapid Point-of-Care Serological Triage Test for Active TB
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Not yet recruiting |
NCT04968886 -
TuBerculosis Viability Interregional Study and Agreement on Biological Tests
|
||
Not yet recruiting |
NCT04485156 -
Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)
|
Phase 3 | |
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT01364324 -
Pharmacokinetics of Anti-tuberculosis Drugs in Gastrectomized Patients
|
||
Active, not recruiting |
NCT04179500 -
A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Volunteers
|
Phase 2 | |
Completed |
NCT05899400 -
A Study to Validate and Improve an Automated Image Analysis Algorithm to Detect Tuberculosis in Sputum Smear Slides
|
||
Completed |
NCT04938596 -
Airborne Preventive Measures to Reduce New TB Infections in Household Contacts
|
N/A | |
Recruiting |
NCT05455112 -
Safety and Efficacy of RUTI® With the Standard of Treatment for Tuberculosis
|
Phase 2 | |
Completed |
NCT03044158 -
GeneXpert Performance Evaluation for Linkage to Tuberculosis Care
|
N/A |